For
UK
audiences
The professional's guide to product selection
The professional's guide to product selection
Mucolytic to facilitate expectoration by reducing sputum viscosity in the case of cystic fibrosis.
Kaftrio 37.5 mg/25 mg/500 mg
Child 6–11 years (body-weight up to 30 kg): 2 tablets, to be taken in the morning and, Ivacaftor 75 mg to be taken in the evening (about 12 hours apart).
Kaftrio 75 mg/50 mg/100 mg
Child over 6 years with body weight greater than 30 kgs and adult: 2 tablets to be taken in the morning in combination with Ivacaftor 150 mg in the evening.
Mucolytic to facilitate expectoration by reducing sputum viscosity in the case of cystic fibrosis.
Tablets
Tablets
Kaftrio 37.5 mg/25 mg/500 mg, 56 tablets
Kaftrio 75 mg/50 mg/100 mg, 56 tablets
Reduction of sputum viscosity.
• Child 2–4 years: 62.5–125 mg, 4 times daily
• Child 5–11 years: 250 mg, 3 times daily
• Over 12 years: initially 2.25 g daily in divided doses, then 1.5 g daily in divided doses as condition improves.
Mucolytic to facilitate expectoration.
• Child 2–4 years: 62.5–125 mg, 4 times daily
• Child 5–11 years: 250 mg, 3 times daily
• Over 12 years: initially 2.25 g daily in divided doses, then 1.5 g daily in divided doses as condition improves.
Mucolytic to facilitate expectoration.
• Child 2–4 years: 62.5–125 mg, 4 times daily
• Child 5–11 years: 250 mg, 3 times daily
• Over 12 years: initially 2.25 g daily in divided doses, then 1.5 g daily in divided doses as condition improves.
Mucolytic to facilitate expectoration.
• Child 2–4 years: 62.5–125 mg, 4 times daily
• Child 5–11 years: 250 mg, 3 times daily
• Over 12 years: initially 2.25 g daily in divided doses, then 1.5 g daily in divided doses as condition improves.
Mucolytic to facilitate expectoration.
• Child 2–4 years: 62.5–125 mg, 4 times daily
• Child 5–11 years: 250 mg, 3 times daily
• Over 12 years: initially 2.25 g daily in divided doses, then 1.5 g daily in divided doses as condition improves.
Mucolytic
Osmohale is used for an indirect osmotic bronchial challenge test which can be used to identify bronchial hyperresponsiveness, a clinical feature of some respiratory conditions such as asthma.
Contraindications: Use with caution in renal impairment and to avoid in pregnancy. The Osmohale test should not be used in patients below 6 years of age due to their inability to provide reproducible spirometric measurements.
There is limited information on the use of Osmohale in patients 6-18 years of age therefore Osmohale is not recommended in this population.
Dose: See manufacturers’ instructions for more information. The test should be repeated until the patient has a positive response or 635 mg has been administered.